Business Context and Reporting Period
Company: Lifevantage Corp (Colorado corporation)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2009
Business Overview: Lifevantage is a dietary supplement company primarily marketing Protandim, a patented supplement designed to combat oxidative stress, and LifeVantage TrueScience Anti-Aging Cream. The company transitioned to a network marketing (multi-level marketing) sales channel in May 2009, hiring approximately 50 new personnel and enrolling over 2,000 independent distributors. The company operates as a single segment and relies heavily on third-party manufacturers.
Key Financial Metrics
| Metric | Fiscal 2009 | Fiscal 2008 |
|---|---|---|
| Net Revenue | $4,141,304 | $3,200,174 |
| Gross Profit | $3,288,500 | $2,504,788 |
| Gross Margin | 79.4% | 78.3% |
| Net Loss | $(9,114,634) | $(2,054,439) |
| Operating Expenses | $11,093,578 | $4,307,595 |
| Cash and Cash Equivalents (End of Period) | $608,795 | $196,883 |
| Working Capital | $(748,000) | $817,000 |
| Derivative Warrant Liability | $8,429,710 | $0 |
Liquidity Note: The company raised approximately $5.0 million in private placements during the fiscal year. As of June 30, 2009, the company had a net capital deficiency and negative working capital.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased by approximately 29.4% ($941,130) compared to the prior year, driven by the launch of the network marketing channel and the recognition of previously deferred retail revenue ($511,000).
- Significant Increase in Loss: Net loss widened by approximately 343% to $9.1 million. This was primarily due to a 157% increase in operating expenses.
- Operating Expenses: Total operating expenses surged from $4.3 million to $11.1 million. Key drivers included:
- Legal Expenses: Approximately $1.6 million incurred defending against a lawsuit filed by Zrii, LLC.
- Network Marketing Launch: Substantial costs associated with hiring new personnel, marketing, and establishing the new sales channel.
- Stock-Based Compensation: Increased non-cash compensation expense from the issuance of options and warrants.
- Derivative Liability: A new derivative warrant liability of $8.4 million was recorded due to the reclassification of warrants issued in private placements that did not meet equity classification criteria under EITF 00-19.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Outlook
Management states that the company is attempting to raise sufficient funds to operate through at least June 30, 2010. Cost reduction initiatives were implemented in August 2009, resulting in the phase-out of 18 positions to streamline operations. The company anticipates continued growth in the network marketing channel but emphasizes that future success depends on the productivity of independent distributors and the ability to secure additional financing.
Risks and Contingencies
- Going Concern: The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and a net capital deficiency.
- Litigation (Zrii, LLC): Zrii filed a complaint alleging trade secret misappropriation, racketeering, and interference with contractual relations, seeking damages of at least $75 million. The company intends to defend vigorously but acknowledges the risk of a material adverse result if the case is not dismissed.
- Liquidity and Capital: The company relies on private placements and bridge loans (including $200,000 from directors and $500,000 from a shareholder in September 2009) to fund operations. Failure to raise additional capital could force a reduction in operations.
- Network Marketing Risks: Success is dependent on recruiting and retaining independent distributors. High turnover or failure to generate sales volume could materially harm the business.
- Regulatory Risks: The company is subject to FDA and FTC regulations regarding dietary supplements and network marketing practices. Non-compliance could result in enforcement actions or product seizures.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of current cash ($609k) and the status of subsequent financing efforts to cover the $5.2 million cash burn from operations.
- Derivative Liability Impact: Assess the volatility of the $8.4 million derivative warrant liability and its potential to further erode equity value based on stock price fluctuations.
- Litigation Status: Monitor the progress of the Zrii, LLC lawsuit and any potential settlements or judgments that could exceed the company's assets.
- Distributor Productivity: Evaluate the actual sales volume generated by the 2,000+ independent distributors to determine if the network marketing model is achieving the projected revenue growth.
- Stock Dilution: Review the impact of outstanding warrants (22.4 million) and options (8.6 million) on future share count and potential dilution from future capital raises.